Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement. Issue 10 (November 2021)

• Record Type: Journal Article
• Authors: Contejean, Adrien; Palmic, Patricia; Kosmider, Olivier; Belhadj, Maya; Willems, Lise; Lengliné, Etienne; Suarez, Felipe; Damotte, Diane; Cottereau, Anne-Ségolène; Asnafi, Vahid; Bouscary, Didier; Burroni, Barbara
• Is Part Of: Anti-cancer drugs. Volume 32:Issue 10(2021)
• Publication Date: 2021-11
• Subjects: myeloid sarcoma -- nelarabine -- next-generation sequencing -- venetoclax; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001105
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Myeloid sarcomas represent a heterogeneous group of diseases with a tumoral presentation of acute myeloid leukemia. The clinical presentation of these hematologic cancers is typically aggressive and thus rapidly fatal in the absence of treatment, which relies on intensive chemotherapy that is sometimes followed by allogeneic hematopoietic stem-cell transplant (AHSCT). However, the global treatment strategy for these lesions is currently not well established. We report the case of a patient presenting with a highly refractory mediastinal myeloid sarcoma with uncommon morphologic and phenotypic characteristics and a clonal TCR rearrangement. The patient's disease was progressive despite multiple courses of intensive chemotherapy and a combination of nelarabine and venetoclax finally led to a complete metabolic response consolidated by an AHSCT. This treatment regimen, which has never been reported before, was very well tolerated especially on the neurologic and hematologic levels. This case underlines the clinical, histologic and molecular heterogeneity of what is called myeloid sarcoma and the importance of next-generation sequencing analysis of the tumor mass with both myeloid and lymphoid panels to better classify this rare entity and identify therapeutic targets. Abstract : Supplemental Digital Content is available in the text.